Compare CCEL & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEL | BTMD |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 39.0M |
| IPO Year | 2022 | 2021 |
| Metric | CCEL | BTMD |
|---|---|---|
| Price | $4.50 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.61 |
| AVG Volume (30 Days) | 11.3K | ★ 117.6K |
| Earning Date | 10-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 722.22 |
| EPS | ★ 0.23 | N/A |
| Revenue | $25,384,279.00 | ★ $192,219,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.45 |
| P/E Ratio | $60.86 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $2.72 | $1.06 |
| 52 Week High | $4.90 | $3.26 |
| Indicator | CCEL | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.17 | 34.19 |
| Support Level | $3.10 | N/A |
| Resistance Level | $4.71 | $1.68 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 73.47 | 32.08 |
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.